Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.
Study Type
OBSERVATIONAL
Enrollment
100
Blood test, laboratory assays
Karolinska University Hospital
Stockholm, Huddinge, Sweden
RECRUITINGDifferences in laboratory values between groupstests
Laboratory values of novel hemostasis tests TTAS, Quantra and OHP correlated to Rotem, TG and conventional coagulation assays. All tests have differnet values.
Time frame: up to 5 years
Correlation between systemic inflammation and hemostasis measured by novel assays
Correlation between systemic inflammation measured by cytokines, NETs and ECV and hemostasis measured by novel assays as in outcome 1
Time frame: uo to 7 years
Number of participant with bleeding
Bleeding defined according to ISTH
Time frame: Up to 7 years
Number of participants with Thrombosis
Splanchnic or non-splanchnic thrombosis
Time frame: Up to 7 years
Number of participants that die
Time frame: Up to 7 years
Number of participant going to transplant
Number of patients getting a transplant, acute, subacute or according to waiting list
Time frame: Up to 7 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.